PMID- 38264278
OWN - NLM
STAT- MEDLINE
DCOM- 20240125
LR  - 20240228
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Effects and safety of Ginkgo biloba on blood metabolism in type 2 diabetes 
      mellitus: a systematic review and meta-analysis.
PG  - 1231053
LID - 10.3389/fendo.2023.1231053 [doi]
LID - 1231053
AB  - BACKGROUND: There has existed controversy regarding the use of Ginkgo biloba 
      (GKB) for blood metabolism among type 2 diabetes mellitus(T2DM) patients, and we 
      tried to analyze the effects and safety of GKB on T2DM patients. METHODS: We 
      conducted a literature search between January 2003 and December 2022 of seven 
      online databases (PubMed, Scopus, Embase, Google Scholar, Web of Sciences, 
      Cochrane Library, and China National Knowledge Infrastructure). A systematic 
      literature review and meta-analysis were performed to compare the effects and 
      safety of GKB among T2DM patients. Four groups of parameters were extracted and 
      analyzed: hemorheology parameters, lipid profile, glycemic control markers, and 
      adverse events. RESULTS: In the end, 13 eligible articles with 11 indicators 
      among 1573 patients were included. In the hemorheology parameters section, GKB 
      showed significantly lower plasma viscosity (PV) (SMD=-0.91, 95%CI [-1.45, 
      -0.36], P<0.01) and hematocrit (Hct) (SMD=-0.60, 95%CI [-0.97, -0.24], P<0.01) 
      than the control group. GKB shoed higher velocity of the dorsalis pedis artery 
      (VDPA) (SMD=0.51, 95%CI [0.26, 0.76], P<0.01) and ankle brachial index (ABI) 
      (SMD=0.71, 95%CI [0.32, 1.10], P<0.01) than the control. In both the lipid 
      profile and glycemic control markers sections, we did not find any difference 
      between GKB and control groups, including total cholesterol (TC), triglyceride 
      (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), hemoglobin 
      A1c (HbA1c), and fasting serum glucose (FSG). In addition, we saw no difference 
      in adverse events (AE). The sensitivity analysis and funnel plot showed that the 
      results in this research were robust and had no publication bias. CONCLUSION: In 
      conclusion, GKB might safely reduce the risk of peripheral arterial or even 
      systemic cardiovascular disease. However, GKB did not directly improve lipid and 
      blood glucose levels in T2DM patients. SYSTEMATIC REVIEW REGISTRATION: 
      https://inplasy.com/, identifier INPLASY202350096.
CI  - Copyright (c) 2024 Zou, Fang, Han, Hu, Meng, Huang, Xu, Lu, Wang, Zhang, Dong, Yu, 
      Guo, Gu and Wang.
FAU - Zou, Huimin
AU  - Zou H
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Fang, Jingxian
AU  - Fang J
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Han, Yu
AU  - Han Y
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Hu, Xue
AU  - Hu X
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Meng, Jian
AU  - Meng J
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Huang, Fang
AU  - Huang F
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Xu, Hui
AU  - Xu H
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Lu, Chengfei
AU  - Lu C
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Wang, Yiwen
AU  - Wang Y
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Zhang, Lili
AU  - Zhang L
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Dong, Xiaohong
AU  - Dong X
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Yu, Yanmei
AU  - Yu Y
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Guo, Yu
AU  - Guo Y
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Gu, Qing
AU  - Gu Q
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
FAU - Wang, Suijun
AU  - Wang S
AD  - Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital 
      Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20240108
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Plant Extracts)
RN  - 0 (Lipids)
SB  - IM
MH  - Humans
MH  - *Ginkgo biloba
MH  - *Diabetes Mellitus, Type 2
MH  - Plant Extracts
MH  - Ankle Brachial Index
MH  - Lipids
PMC - PMC10804948
OTO - NOTNLM
OT  - GKB
OT  - Ginkgo biloba
OT  - T2DM
OT  - meta-analysis
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/24 06:42
MHDA- 2024/01/25 06:43
PMCR- 2023/01/01
CRDT- 2024/01/24 03:49
PHST- 2023/06/01 00:00 [received]
PHST- 2023/11/27 00:00 [accepted]
PHST- 2024/01/25 06:43 [medline]
PHST- 2024/01/24 06:42 [pubmed]
PHST- 2024/01/24 03:49 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1231053 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2024 Jan 8;14:1231053. doi: 
      10.3389/fendo.2023.1231053. eCollection 2023.